

Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia
David J. Kuter, et al.

Supplemental Material

Supplemental Table 1. Additional platelet response endpoints in the LTE

Platelet responses, n/n (%)	All LTE patients (n = 16)
$\geq 50 \times 10^9/L$ in $\geq 50\%$ of monthly visits*	13/14 (93) [†]
$\geq 50 \times 10^9/L$ in $\geq 50\%$ of quarterly visits in the last 12 months	7/7 (100) [†]
$\geq 100 \times 10^9/L$ at any point	13/16 (81)

LTE, long-term extension.

*Included patients with platelet count visits between LTE cycle 7, day 1 and LTE cycle 12, day 1.

[†]Denominator indicates the number of patients who have progressed far enough in the LTE to be eligible for monthly or quarterly visit assessments.